Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | PARL | Q9H300 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL11134259 | 0.78 | LTA4H (0.45) | MGLL | |
| SCHEMBL29790853 | 0.78 | LTA4H (0.45) | MGLL | |
| SCHEMBL20943 | 0.78 | LTA4H (0.45) | MGLL | |
| SCHEMBL31506395 | 0.76 | LTA4H (0.43) | MGLL | |
| SCHEMBL31506397 | 0.76 | LTA4H (0.43) | MGLL | |
| SCHEMBL31674356 | 0.76 | LTA4H (0.43) | MGLL | |
| SCHEMBL5883808 | 0.76 | LTA4H (0.43) | MGLL | |
| SCHEMBL11350262 | 0.76 | LTA4H (0.43) | MGLL | |
| SCHEMBL31506398 | 0.76 | LTA4H (0.43) | MGLL | |
| SCHEMBL13805761 | 0.76 | LTA4H (0.43) | PKMMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018033593-A1 | SOFOSBUVIR DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | SANDOZ AG (CH) | 2018-02-22 | — | — | WO | disclosed |
| US-20150119356-A1 | Ophthalmic Viscoelastic Device | CARL ZEISS MEDITEC AG (DE) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119356-A1 | Ophthalmic Viscoelastic Device | UACA, ICAM1, VIM | ALOX12 355/4885PARL 2861/4885ALDH1A1 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.